S7 Table. Pathway-level analysis in oligometastatic and polymetastatic NSCLC patients

Pathway	Oligometastasis (n=77)		Polymetastasis (n=21)		p-value
	Mutated pathway number	Mutated pathway frequency (%)	Mutated pathway number	Mutated pathway frequency (%)	
hsa05230:Central carbon metabolism in cancer	68	88.31	19	90.48	1.000
hsa05202:Transcriptional misregulation in cancer	54	70.13	16	76.19	0.782
hsa05166:HTLV-I infection	64	83.12	16	76.19	0.528
hsa04919:Thyroid hormone signaling pathway	57	74.03	17	80.95	0.570
hsa04370:VEGF signaling pathway	20	25.97	5	23.81	0.991
hsa04151:PI3K-Akt signaling pathway	67	87.01	20	95.24	0.448
hsa04150:mTOR signaling pathway	22	28.57	3	14.29	0.252
hsa04115:p53 signaling pathway	56	72.73	14	66.67	0.591
hsa04110:Cell cycle	64	83.12	15	71.43	0.230
hsa04068:FoxO signaling pathway	61	79.22	15	71.43	0.534
hsa04066:HIF-1 signaling pathway	50	64.94	19	90.48	**0.027**
hsa04015:Rap1 signaling pathway	63	81.82	18	85.71	1.000
hsa04014:Ras signaling pathway	61	79.22	18	85.71	0.756
hsa04012:ErbB signaling pathway	59	76.62	19	90.48	0.223
hsa04210:Apoptosis	51	66.23	NA	NA	NA

Bold indicates statistical significance, $p < 0.05$. NA, not available; NSCLC, non–small cell lung cancer.